China biotech surge fuels licensing race

China's biotech ecosystem has undergone a remarkable transformation over the past two decades, evolving from a market dominated by branded generics with minimal R&D into a powerhouse of innovation characterized by speed, scale, and regulatory efficiency. In 2025 alone, China approved a record 76 innovative drugs—up from 48 the previous year—and accounted for about 30 percent of the global biopharma pipeline, a dramatic rise from just 2 percent a decade earlier, according to McKinsey. This rapid development pace is bolstered by streamlined R&D processes that enable companies to progress from target identification to clinical trials 1.5 times faster than the global benchmark, with patient enrollment accelerating two to five times faster, making China an exceptionally attractive hub for drug development.

Global pharmaceutical giants like Merck are strategically pivoting toward China not merely as a lower-cost base but as a vital innovation and growth engine. Andre Musto of Merck highlights China's 'innovation capacity,' 'vast market,' and leadership in AI and digitalization as critical drivers underpinning long-term strategic cooperation. This shift is reflected in the surge of outbound licensing deals involving Chinese innovative drugs, which exceeded $130 billion in 2025, with over 150 deals completed, signaling China's emergence as a key source of cutting-edge assets. Merck's commitment, rooted in a 90-year presence, underscores the industry's recognition of China as a cornerstone for future healthcare innovation and market expansion.

China's biotech sector is emblematic of the country's broader industrial upgrading, where the 'next new three'—AI, robotics, and innovative drugs—are driving a strategic shift from manufacturing volume to high-end innovation focused on original research and core technologies. This evolution is evident not only in pharmaceutical licensing dominance, with Chinese firms securing eight of the world's top 10 deals in early 2026 and outbound technology licensing transactions hitting $110 billion in the first half of the year, but also in global technology exports such as DEEP Robotics’ quadruped robot deployed at Switzerland’s Leibstadt Nuclear Power Plant. Concurrently, China's export structure is optimizing toward knowledge-intensive services, which surged 12.2 percent in early 2026, reflecting a deliberate move to capitalize on innovation-driven market dynamics and strengthen its position in global industrial chains.

Success in China's evolving biotech market increasingly depends on companies developing capabilities beyond basic manufacturing and commercial operations, focusing instead on innovation and local market adaptation. As Franck Le Deu notes, firms that differentiate themselves by building these advanced capabilities are better positioned to thrive amid China's rapidly expanding innovation ecosystem and growing access to capital markets. This strategic emphasis aligns with the broader trend of global pharma investing heavily in China to harness its unique blend of scientific advancement, regulatory agility, and market potential.

By mid-2026, the US-China biotech rivalry has escalated into a complex geopolitical and regulatory standoff, with China’s state-backed initiatives disrupting traditional capital flows and innovation frameworks, thereby challenging regulatory fairness and intensifying national security concerns. In response, bipartisan licensing review bills have emerged in the US as a strategic attempt to level the playing field without resorting to outright protectionism, marking a pivotal moment for healthcare policy and regulatory strategies aimed at balancing competition with open innovation.

China’s updated export control regulations have introduced new vulnerabilities for the US pharmaceutical supply chain by enabling Beijing to interpret routine compliance activities as threats to its industrial base, potentially triggering retaliatory measures such as licensing delays and tighter import/export controls. As Gerren McHam emphasizes, this overlapping regulatory landscape demands robust internal governance and clear escalation protocols within US pharma companies to navigate the strategic implications of trade decisions, yet industry awareness of these risks remains surprisingly limited.

The intensifying US-China biotech competition, fueled by China’s regulatory reforms, talent repatriation, and government prioritization since 2017, has prompted high-profile US policy debates involving figures like Scott Gottlieb and Gina Raimondo focused on curbing China’s rapid ascendancy. However, some industry leaders advocate for a nuanced approach that acknowledges China’s rise as both a competitive threat and a collaborative opportunity, underscoring the globalized nature of biotech innovation which complicates containment efforts and ultimately serves patient interests worldwide.

Industry leaders caution against protectionist measures like the Biotech Investment National Security Act, arguing that such policies create uncertainty and hinder innovation by effectively banning collaboration with Chinese firms. Instead, they advocate for a strategy reminiscent of the US response to Sputnik—doubling down on domestic investment to outpace China’s biotech advancements rather than isolating from them. This approach emphasizes accelerating innovation through robust funding and ecosystem development, ensuring the US maintains leadership without resorting to restrictive bans that could backfire.

The biotech sector’s strength lies in its openness to global talent and collaboration, as exemplified by Revolution Medicines’ pancreatic cancer treatment developed by a diverse team including an Iranian immigrant’s son and a British scientist. Industry voices stress that attracting and retaining the world’s best minds, rather than imposing immigration restrictions, is crucial for solving complex biomedical challenges. This inclusive mindset underscores that innovation thrives when scientific exchange transcends geopolitical tensions, fostering breakthroughs that benefit patients worldwide.

European biotech leaders, represented by Franck, advocate for a nuanced, fact-based dialogue that moves beyond polarized views of China as either a threat or an ally. They propose cautious partnerships leveraging China’s strengths in early-stage clinical trials and data access while safeguarding intellectual property and reshoring manufacturing to Europe. This balanced approach aims to build resilient, win-win models over a decade-long horizon that enhance patient access, innovation sovereignty, and biosecurity without succumbing to political extremes.